Dr Reddy’s Laboratories announces the launch of Invista (dasatinib) in India

Dr Reddy’s Laboratories announced the launch of Invista, a formulation of Dasatinib that is bioequivalent to the innovator brand. It is indicated for the treatment of chronic accelerated or myeloid or lymphoid blast phase and newly diagnosed in chronic phase adult patients with Chronic Myeloid Leukemia (CML) in India.

Commenting on the launch, M V Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr Reddy’s Laboratories said, "We are pleased to bring this important and complex product to the market in India. The development and launch of Invista is a significant step forward in improving access to medicines at an affordable price for CML patients in India.

Dr Reddy’s Invista is available in strengths of 50, 70 and 100 mg tablets.

Chronic Myeloid Leukemia is a type of blood-cell cancer that begins in the bone marrow. The median age of the patients in India is a decade earlier than the west, and every year about nine thousand new patients are diagnosed in the country.

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.